Broadly neutralizing anti-HIV antibodies prevent HIV infection of mucosal tissue Ex vivo

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 904-912

  Scott, Yanille M ^a   Park, Seo Young ^b   Dezzutti, Charlene S ^b,c  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4E10 ANTIBODY; ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MICROBICIDE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PG16 ANTIBODY; PG9 ANTIBODY; UNCLASSIFIED DRUG; VRC01 ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; CHO CELL LINE; COLON; CRICETULUS; DRUG EFFECTS; FEMALE; HIV INFECTIONS; IMMUNOLOGY; MALE; MUCOSA; ORGAN CULTURE TECHNIQUE; PRECLINICAL STUDY; PROCEDURES; SPERM; TOPICAL DRUG ADMINISTRATION; TRANSMISSION; UTERINE CERVIX; VIROLOGY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CERVIX UTERI; CHO CELLS; COLON; CRICETULUS; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MUCOUS MEMBRANE; ORGAN CULTURE TECHNIQUES; SEMEN;

EID: 84957899888     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02097-15     Document Type: Article

References (40)

1. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF. 2011. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11:750-759. http://dx.doi.org/10.1016/S1473-3099(11)70149-9.
2. Jennings R, Clegg A. 1993. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. J Antimicrob Chemother 32:71-82. http://dx.doi.org/10.1093/jac/32.1.71.
3. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, Karim SS, Masse B, Perriens J, Laga M. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977. http://dx.doi.org/10.1016/S0140-6736(02)11079-8.
4. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Keller MJ, Herold BC. 2009. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200:599-608. http://dx.doi.org/10.1086/600867.
5. Dezzutti CS, Brown ER, Moncla B, Russo J, Cost M, Wang L, Uranker K, Kunjara Na Ayudhya RP, Pryke K, Pickett J, Leblanc MA, Rohan LC. 2012. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One 7:e48328. http://dx.doi.org/10.1371/journal.pone.0048328.
6. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Masse B, Hillier SL, Soto-Torres L. 2011. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (London, England) 25:957-966. http://dx.doi.org/10.1097/QAD.0b013e32834541d9.
7. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987. http://dx.doi.org/10.1016/S0140-6736(08)61842-5.
8. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
9. + T cell decline and high viral load during acute infection. J Virol 85:4828-4840. http://dx.doi.org/10.1128/JVI.00198-11.
10. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:55-62. http://dx.doi.org/10.1038/nature13036.
11. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. 2013. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153:126-138. http://dx.doi.org/10.1016/j.cell.2013.03.018.
12. Eroshkin AM, Leblanc A, Weekes D, Post K, Li Z, Rajput A, Butera ST, Burton DR, Godzik A. 2014. bNAber: database of broadly neutralizing HIV antibodies. Nucleic Acids Res 42:D1133-D1139. http://dx.doi.org/10.1093/nar/gkt1083.
13. Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H. 2011. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol 85:7236-7245. http://dx.doi.org/10.1128/JVI.00196-11.
14. Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R. 2014. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 7:46-56. http://dx.doi.org/10.1038/mi.2013.23.
15. Veselinovic M, Neff CP, Mulder LR, Akkina R. 2012. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432:505-510. http://dx.doi.org/10.1016/j.virol.2012.06.025.
16. Whaley KJ, Hiatt A, Zeitlin L. 2011. Emerging antibody products and Nicotiana manufacturing. Hum Vaccin 7:349-356. http://dx.doi.org/10.4161/hv.7.3.14266.
17. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497.
18. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002.
19. Cummins JE, Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA, Paxton L, Dezzutti CS. 2007. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 51:1770-1779. http://dx.doi.org/10.1128/AAC.01129-06.
20. Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE, Jr, Fink A, Gilmore GT, Staley C, Ward A, Ali O, Binderow S, Cohen S, Grohskopf LA, Paxton L, Hart CE, Dezzutti CS. 2005. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 192:1545-1556. http://dx.doi.org/10.1086/462424.
21. Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, Guzman E, Wang R, Herold BC, Keller MJ. 2007. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 196:1394-1402. http://dx.doi.org/10.1086/522606.
22. Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Gimenez-Gallego G, Sanchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F. 2007. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131:1059-1071. http://dx.doi.org/10.1016/j.cell.2007.10.014.
23. Bouvet JP, Gresenguet G, Belec L. 1997. Vaginal pH neutralization by semen as a cofactor of HIV transmission. Clin Microbiol Infect 3:19-23.
24. Doncel GF, Anderson S, Zalenskaya I. 2014. Role of semen in modulating the female genital tract microenvironment - implications for HIV transmission. Am J Reprod Immunol (New York, NY) 71:564-574. http://dx.doi.org/10.1111/aji.12231.
25. Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, Cone R, Hope TJ, Hanes J. 2009. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 83:11196-11200. http://dx.doi.org/10.1128/JVI.01899-08.
26. Tevi-Benissan C, Belec L, Levy M, Schneider-Fauveau V, Si Mohamed A, Hallouin MC, Matta M, Gresenguet G. 1997. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 4:367-374.
27. Gross M, Holte SE, Marmor M, Mwatha A, Koblin BA, Mayer KH. 2000. Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team. J Acquir Immune Defic Syndr 24:393-398.
28. Tian LH, Peterman TA, Tao G, Brooks LC, Metcalf C, Malotte CK, Paul SM, Douglas JM, Jr. 2008. Heterosexual anal sex activity in the year after an STD clinic visit. Sex Transm Dis 35:905-909. http://dx.doi.org/10.1097/OLQ.0b013e318181294b.
29. Tucker S, Krishna R, Prabhakar P, Panyam S, Anand P. 2012. Exploring dynamics of anal sex among female sex workers in Andhra Pradesh. Indian J Sex Transm Dis 33:9-15. http://dx.doi.org/10.4103/0253-7184.93787.
30. McGowan I, Hoesley C, Cranston RD, Andrew P, Janocko L, Dai JY, Carballo-Dieguez A, Ayudhya RK, Piper J, Hladik F, Mayer K. 2013. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS One 8:e60147. http://dx.doi.org/10.1371/journal.pone.0060147.
31. Dezzutti CS, Shetler C, Mahalingam A, Ugaonkar SR, Gwozdz G, Buckheit KW, Buckheit RW, Jr. 2012. Safety and efficacy of tenofovir/IQP-0528 combination gels - A dual compartment microbicide for HIV-1 prevention. Antiviral Res 96:221-225. http://dx.doi.org/10.1016/j.antiviral.2012.08.004.
32. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9:343-346. http://dx.doi.org/10.1038/nm833.
33. Thompson CG, Cohen MS, Kashuba AD. 2013. Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr 63(Suppl 2):S240-S247. http://dx.doi.org/10.1097/QAI.0b013e3182986ff8.
34. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. 2010. Targeting Trojan horse leukocytes for HIV prevention. AIDS (London, England) 24:163-187. http://dx.doi.org/10.1097/QAD.0b013e32833424c8.
35. To EE, Hendrix CW, Bumpus NN. 2013. Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues. Biochem Pharmacol 86:979-990. http://dx.doi.org/10.1016/j.bcp.2013.08.013.
36. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78:13232-13252. http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004.
37. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BF. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol (Baltimore, MD) 178:4424-4435.
38. Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, Wyatt RT. 2011. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol 85:8217-8226. http://dx.doi.org/10.1128/JVI.00756-11.
39. French KC, Makhatadze GI. 2012. Core sequence of PAPf39 amyloid fibrils and mechanism of pH-dependent fibril formation: the role of monomer conformation. Biochemistry 51:10127-10136. http://dx.doi.org/10.1021/bi301406d.
40. Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little F, Mansoor LE, Naranbhai V, Lauffenburger DA, Ronacher K, Walzl G, Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool Karim Q, Abdool Karim SS. 2015. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis 61:260-269. http://dx.doi.org/10.1093/cid/civ298.